Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

The primary objective of this study is to compare the objective response rate (ORR) of patients with LA-HNSCC, treated with induction of EGFR-ADC MRG003 and anti PD-1 Pucotenlimab versus EGFR-ADC MRG003 alone before chemoradiotherapy. People eligible to participate in this study must be between the ages of 18 and 75 and have locally advanced squamous cell carcinoma of the head and neck requiring treatment with chemoradiotherapy (cisplatin combined with radiotherapy). Half of the research participants will receive MRG003 alone as induction before radiochemotherapy and the other half will rece

Trial Details

NCT ID
NCT06959108
Phase
PHASE2
Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Pucotenlimab
  • MRG003
Locations (sample)
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Evaluable tumor burden assessed by H\&N-computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on RECIST v 1.1
  • Patients eligible to cisplatin-based chemotherapy
  • No hearing loss by clinical assessment or ≤ grade 2 hearing impairment (according to NCICTCAE v.5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →